Personal genomics company 23andMe has partnered with pharmaceutical giant Pfizer to explore possible genetic factors associated with Inflammatory Bowel Disease, a chronic illness that affects some 1.4 million people in the United States. The companies plan to enroll and analyze the genomes of 10,000 people diagnosed with Crohn’s disease or ulcerative colitis. “We are excited to team up with Pfizer to take an innovative, consumer-centered approach to try to understand the fundamentals of inflammatory bowel disease and the variability of treatment response,” 23andMe CEO Anne Wojcicki said in a statement. Read more about the study here.
This article originally appeared on Recode.net.
